PURPOSE: We previously showed that nuclear localization of the actin-binding protein, filamin A (FlnA), corresponded to hormone-dependence in prostate cancer. Intact FlnA (280 kDa, cytoplasmic) cleaved to a 90 kDa fragment which translocated to the nucleus in hormone-naïve cells, whereas in hormone-refractory cells, FlnA was phosphorylated, preventing its cleavage and nuclear translocation. We have examined whether FlnA localization determines a propensity to metastasis in advanced androgen-independent prostate cancer. EXPERIMENTAL DESIGN: We examined, by immunohistochemistry, FlnA localization in paraffin-embedded human prostate tissue representing different stages of progression. Results were correlated with in vitro studies in a cell model of prostate cancer. RESULTS: Nuclear FlnA was significantly higher in benign prostate (0.6612 +/- 0.5888), prostatic intraepithelial neoplasia (PIN; 0.6024 +/- 0.4620), and clinically localized cancers (0.69134 +/- 0.5686) compared with metastatic prostate cancers (0.3719 +/- 0.4992, P = 0.0007). Cytoplasmic FlnA increased from benign prostate (0.0833 +/- 0.2677), PIN (0.1409 +/- 0.2293), localized cancers (0.3008 +/- 0.3762, P = 0.0150), to metastases (0.7632 +/- 0.4414, P < 0.00001). Logistic regression of metastatic versus nonmetastatic tissue yielded the area under the receiver operating curve as 0.67 for nuclear-FlnA, 0.79 for cytoplasmic-FlnA, and 0.82 for both, indicating that metastasis correlates with cytoplasmic to nuclear translocation. In vitro studies showed that cytoplasmic localization of FlnA induced cell invasion whereas nuclear translocation of the protein inhibited it. FlnA dephosphorylation with the protein kinase A inhibitor H-89 facilitated FlnA nuclear translocation, resulting in decreased invasiveness and AR transcriptional activity, and induced sensitivity to androgen withdrawal in hormone-refractory cells. CONCLUSIONS: The data presented in this study indicate that in prostate cancer, metastasis correlates with cytoplasmic localization of FlnA and may be prevented by cleavage and subsequent nuclear translocation of this protein.
PURPOSE: We previously showed that nuclear localization of the actin-binding protein, filamin A (FlnA), corresponded to hormone-dependence in prostate cancer. Intact FlnA (280 kDa, cytoplasmic) cleaved to a 90 kDa fragment which translocated to the nucleus in hormone-naïve cells, whereas in hormone-refractory cells, FlnA was phosphorylated, preventing its cleavage and nuclear translocation. We have examined whether FlnA localization determines a propensity to metastasis in advanced androgen-independent prostate cancer. EXPERIMENTAL DESIGN: We examined, by immunohistochemistry, FlnA localization in paraffin-embedded human prostate tissue representing different stages of progression. Results were correlated with in vitro studies in a cell model of prostate cancer. RESULTS: Nuclear FlnA was significantly higher in benign prostate (0.6612 +/- 0.5888), prostatic intraepithelial neoplasia (PIN; 0.6024 +/- 0.4620), and clinically localized cancers (0.69134 +/- 0.5686) compared with metastatic prostate cancers (0.3719 +/- 0.4992, P = 0.0007). Cytoplasmic FlnA increased from benign prostate (0.0833 +/- 0.2677), PIN (0.1409 +/- 0.2293), localized cancers (0.3008 +/- 0.3762, P = 0.0150), to metastases (0.7632 +/- 0.4414, P < 0.00001). Logistic regression of metastatic versus nonmetastatic tissue yielded the area under the receiver operating curve as 0.67 for nuclear-FlnA, 0.79 for cytoplasmic-FlnA, and 0.82 for both, indicating that metastasis correlates with cytoplasmic to nuclear translocation. In vitro studies showed that cytoplasmic localization of FlnA induced cell invasion whereas nuclear translocation of the protein inhibited it. FlnA dephosphorylation with the protein kinase A inhibitor H-89 facilitated FlnA nuclear translocation, resulting in decreased invasiveness and AR transcriptional activity, and induced sensitivity to androgen withdrawal in hormone-refractory cells. CONCLUSIONS: The data presented in this study indicate that in prostate cancer, metastasis correlates with cytoplasmic localization of FlnA and may be prevented by cleavage and subsequent nuclear translocation of this protein.
Authors: T P Stossel; J Condeelis; L Cooley; J H Hartwig; A Noegel; M Schleicher; S S Shapiro Journal: Nat Rev Mol Cell Biol Date: 2001-02 Impact factor: 94.444
Authors: Stephen P Robertson; Stephen R F Twigg; Andrew J Sutherland-Smith; Valérie Biancalana; Robert J Gorlin; Denise Horn; Susan J Kenwrick; Chong A Kim; Eva Morava; Ruth Newbury-Ecob; Karen H Orstavik; Oliver W J Quarrell; Charles E Schwartz; Deborah J Shears; Mohnish Suri; John Kendrick-Jones; Andrew O M Wilkie Journal: Nat Genet Date: 2003-03-03 Impact factor: 38.330
Authors: Gopalakrishnapillai Anilkumar; Sigrid A Rajasekaran; Song Wang; Oliver Hankinson; Neil H Bander; Ayyappan K Rajasekaran Journal: Cancer Res Date: 2003-05-15 Impact factor: 12.701
Authors: J C Evans; J McCarthy; C Torres-Fuentes; J F Cryan; J Ogier; R Darcy; R W Watson; C M O'Driscoll Journal: Gene Ther Date: 2015-05-25 Impact factor: 5.250
Authors: Rosalinda M Savoy; Liqun Chen; Salma Siddiqui; Frank U Melgoza; Blythe Durbin-Johnson; Christiana Drake; Maitreyee K Jathal; Swagata Bose; Thomas M Steele; Benjamin A Mooso; Leandro S D'Abronzo; William H Fry; Kermit L Carraway; Maria Mudryj; Paramita M Ghosh Journal: Endocr Relat Cancer Date: 2015-03-10 Impact factor: 5.678
Authors: Liqun Chen; Salma Siddiqui; Swagata Bose; Benjamin Mooso; Alfredo Asuncion; Roble G Bedolla; Ruth Vinall; Clifford G Tepper; Regina Gandour-Edwards; Xubao Shi; Xiao-Hua Lu; Javed Siddiqui; Arul M Chinnaiyan; Rohit Mehra; Ralph W Devere White; Kermit L Carraway; Paramita M Ghosh Journal: Cancer Res Date: 2010-06-29 Impact factor: 12.701
Authors: Benjamin A Mooso; Ruth L Vinall; Clifford G Tepper; Rosalinda M Savoy; Jean P Cheung; Sheetal Singh; Salma Siddiqui; Yu Wang; Roble G Bedolla; Anthony Martinez; Maria Mudryj; Hsing-Jien Kung; Ralph W Devere White; Paramita M Ghosh Journal: Endocr Relat Cancer Date: 2012-11-09 Impact factor: 5.678